{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:30:00Z","timestamp":1791189000508,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>FSGS is the primary cause of childhood nephrotic syndrome leading to ESRD. Permeability factors, including circulating serum soluble urokinase-type plasminogen activator receptor (suPAR), have been postulated as putative causes in adults with primary FSGS. Similar results have yet to be proven in children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>This cross-sectional single-center study assessed the association of serum suPAR in children with FSGS or other glomerular and nonglomerular kidney diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study examined 110 samples retrieved from 99 individuals (between January 2011 and April 2012), aged 1\u201321 years; of these individuals, 20 had primary FSGS, 24 had non-FSGS glomerular disease, 26 had nonglomerular kidney disease, and 29 were healthy controls. suPAR levels were not significantly different in children with FSGS, non-FSGS glomerular disease, and healthy controls (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt;0.05). However, suPAR levels (median [25%\u201375%]) were higher in children with nonglomerular kidney disease (3385 pg\/ml [2695\u20134392]) versus FSGS (2487 pg\/ml [2191\u20133351];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.05). Female patients with nephrotic-range proteinuria (U-Pr\/Cr &gt;2) had lower suPAR levels than those without proteinuria (2380 pg\/ml [2116\u20132571] versus 3125 pg\/ml [2516\u20134198], respectively;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). This trend was not seen among male participants; suPAR levels in all female participants were lower than in male participants (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.03). Thirty-four patients studied were kidney transplant recipients; transplant status was not associated with suPAR levels in patients with FSGS or non-FSGS diagnoses, independent of proteinuria, race, or sex (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt;0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>On the basis of these results, circulating suPAR is unlikely the leading cause for childhood idiopathic FSGS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.07680712","type":"journal-article","created":{"date-parts":[[2013,4,25]],"date-time":"2013-04-25T23:52:21Z","timestamp":1366933941000},"page":"1304-1311","source":"Crossref","is-referenced-by-count":93,"title":["Serum Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Idiopathic FSGS in Children"],"prefix":"10.2215","volume":"8","author":[{"given":"Margret E.","family":"Bock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Gallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig B.","family":"Langman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20230811","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMra1106556","article-title":"Focal segmental glomerulosclerosis.","volume":"365","author":"D\u2019Agati","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-7-20230811","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","article-title":"Pathogenesis of lipoid nephrosis: A disorder of T-cell function.","volume":"2","author":"Shalhoub","year":"1974","journal-title":"Lancet"},{"key":"R3-7-20230811","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0002-9343(92)90267-F","article-title":"Recurrent focal glomerulosclerosis: Natural history and response to therapy.","volume":"92","author":"Artero","year":"1992","journal-title":"Am J Med"},{"key":"R5-7-20230811","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1056\/NEJM199604043341402","article-title":"Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis.","volume":"334","author":"Savin","year":"1996","journal-title":"N Engl J Med"},{"key":"R6-7-20230811","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/jca.20129","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice: Evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.","volume":"22","author":"Szczepiorkowski","year":"2007","journal-title":"J Clin Apher"},{"key":"R7-7-20230811","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1056\/NEJMc1202500","article-title":"Resolution of recurrent focal segmental glomerulosclerosis after retransplantation.","volume":"366","author":"Gallon","year":"2012","journal-title":"N Engl J Med"},{"key":"R8-7-20230811","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00007890-200202150-00009","article-title":"Proteinuria after injection of human focal segmental glomerulosclerosis factor.","volume":"73","author":"Sharma","year":"2002","journal-title":"Transplantation"},{"key":"R10-7-20230811","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.","volume":"17","author":"Wei","year":"2011","journal-title":"Nat Med"},{"key":"R11-7-20230811","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1542\/peds.105.6.1242","article-title":"Evaluation and management of proteinuria and nephrotic syndrome in children: Recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE).","volume":"105","author":"Hogg","year":"2000","journal-title":"Pediatrics"},{"key":"R12-7-20230811","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00467-006-0103-9","article-title":"Profiling proteinuria in pediatric patients.","volume":"21","author":"Abitbol","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"R13-7-20230811","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD.","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R15-7-20230811","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1007\/s00134-012-2613-1","article-title":"Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: A systematic review.","volume":"38","author":"Backes","year":"2012","journal-title":"Intensive Care Med"},{"key":"R16-7-20230811","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/clinchem\/43.10.1868","article-title":"ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients.","volume":"43","author":"Stephens","year":"1997","journal-title":"Clin Chem"},{"key":"R17-7-20230811","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/cc10037","article-title":"Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.","volume":"15","author":"Koch","year":"2011","journal-title":"Crit Care"},{"key":"R19-7-20230811","first-page":"1843","article-title":"The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.","volume":"58","author":"Sier","year":"1998","journal-title":"Cancer Res"},{"key":"R20-7-20230811","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00126334-200404010-00002","article-title":"Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients.","volume":"35","author":"Ostrowski","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R21-7-20230811","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.58.8.488","article-title":"Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: Increased concentrations in rheumatoid arthritis.","volume":"58","author":"Slot","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"R22-7-20230811","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3109\/00365521.2010.539253","article-title":"Blood chemistry markers for evaluation of inflammatory activity in Crohn\u2019s disease during infliximab therapy.","volume":"46","author":"L\u00f6nnkvist","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"R24-7-20230811","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2796.2011.02372.x","article-title":"suPAR - a future risk marker in bacteremia.","volume":"270","author":"Eugen-Olsen","year":"2011","journal-title":"J Intern Med"},{"key":"R25-7-20230811","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11010-008-9925-z","article-title":"Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR\/CD87).","volume":"321","author":"Pliyev","year":"2009","journal-title":"Mol Cell Biochem"},{"key":"R26-7-20230811","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00467-008-0972-1","article-title":"Methylated arginine derivatives in children and adolescents with chronic kidney disease.","volume":"24","author":"Brooks","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"R27-7-20230811","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1681\/ASN.2012030302","article-title":"Circulating suPAR in two cohorts of primary FSGS.","volume":"23","author":"Wei","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R28-7-20230811","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.thromres.2011.10.034","article-title":"Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: The SAfrEIC-study.","volume":"130","author":"Schutte","year":"2012","journal-title":"Thromb Res"},{"key":"R29-7-20230811","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3109\/00365521.2012.699549","article-title":"Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease.","volume":"8-9","author":"Kolho","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"R30-7-20230811","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4137\/BMI.S8326","article-title":"Detection of suPAR in the saliva of healthy young adults: Comparison with plasma levels.","volume":"6","author":"Gustafsson","year":"2011","journal-title":"Biomark Insights"},{"key":"R31-7-20230811","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2796.2010.02252.x","article-title":"Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.","volume":"268","author":"Eugen-Olsen","year":"2010","journal-title":"J Intern Med"},{"key":"R32-7-20230811","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/ki.2012.32","article-title":"Serum-soluble urokinase receptor concentration in primary FSGS.","volume":"81","author":"Maas","year":"2012","journal-title":"Kidney Int"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201308000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:43:17Z","timestamp":1786369397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201308000-00007"}},"subtitle":["A Single-Center Report"],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.07680712","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}